File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines

TitleCross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines
Authors
KeywordsCOVID-19
Immune protection
Inactivated vaccine
Neutralizing antibodies
SARS-CoV-2 variants of concern
Issue Date2022
Citation
International Journal of Biological Sciences, 2022, v. 18, n. 12, p. 4781-4791 How to Cite?
AbstractRapid development and successful use of vaccines against SARS-CoV-2 might hold the key to curb the ongoing pandemic of COVID-19. Emergence of vaccine-evasive SARS-CoV-2 variants of concern (VOCs) has posed a new challenge to vaccine design and development. One urgent need is to determine what types of variant-specific and bivalent vaccines should be developed. Here, we compared homotypic and heterotypic protection against SARS-CoV-2 infection of hamsters with monovalent and bivalent whole-virion inactivated vaccines derived from representative VOCs. In addition to the ancestral SARS-CoV-2 Wuhan strain, Delta (B.1.617.2; δ) and Theta (P.3; θ) variants were used in vaccine preparation. Additional VOCs including Omicron (B.1.1.529) and Alpha (B.1.1.7) variants were employed in the challenge experiment. Consistent with previous findings, Omicron variant exhibited the highest degree of immune evasion, rendering all different forms of inactivated vaccines substantially less efficacious. Notably, monovalent and bivalent Delta variant-specific inactivated vaccines provided optimal protection against challenge with Delta variant. Yet, some cross-variant protection against Omicron and Alpha variants was seen with all monovalent and bivalent inactivated vaccines tested. Taken together, our findings support the notion that an optimal next-generation inactivated vaccine against SARS-CoV-2 should contain the predominant VOC in circulation. Further investigations are underway to test whether a bivalent vaccine for Delta and Omicron variants can serve this purpose.
Persistent Identifierhttp://hdl.handle.net/10722/315207
ISSN
2023 Impact Factor: 8.2
2023 SCImago Journal Rankings: 2.114
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYe, Zi Wei-
dc.contributor.authorFan, Yilan-
dc.contributor.authorTang, Kaiming-
dc.contributor.authorOng, Chon Phin-
dc.contributor.authorLuo, Cuiting-
dc.contributor.authorChung, Hon Lam-
dc.contributor.authorLeong, Tsun Lam-
dc.contributor.authorLiang, Ronghui-
dc.contributor.authorLui, Wai Yin-
dc.contributor.authorZhou, Runhong-
dc.contributor.authorCheng, Yun-
dc.contributor.authorLu, Lu-
dc.contributor.authorCheung, Pak Hin Hinson-
dc.contributor.authorChan, Jasper Fuk Woo-
dc.contributor.authorChen, Zhiwei-
dc.contributor.authorYuen, Kwok Yung-
dc.contributor.authorYuan, Shuofeng-
dc.contributor.authorTo, Kelvin Kai Wang-
dc.contributor.authorJin, Dong Yan-
dc.date.accessioned2022-08-05T10:18:03Z-
dc.date.available2022-08-05T10:18:03Z-
dc.date.issued2022-
dc.identifier.citationInternational Journal of Biological Sciences, 2022, v. 18, n. 12, p. 4781-4791-
dc.identifier.issn1449-2288-
dc.identifier.urihttp://hdl.handle.net/10722/315207-
dc.description.abstractRapid development and successful use of vaccines against SARS-CoV-2 might hold the key to curb the ongoing pandemic of COVID-19. Emergence of vaccine-evasive SARS-CoV-2 variants of concern (VOCs) has posed a new challenge to vaccine design and development. One urgent need is to determine what types of variant-specific and bivalent vaccines should be developed. Here, we compared homotypic and heterotypic protection against SARS-CoV-2 infection of hamsters with monovalent and bivalent whole-virion inactivated vaccines derived from representative VOCs. In addition to the ancestral SARS-CoV-2 Wuhan strain, Delta (B.1.617.2; δ) and Theta (P.3; θ) variants were used in vaccine preparation. Additional VOCs including Omicron (B.1.1.529) and Alpha (B.1.1.7) variants were employed in the challenge experiment. Consistent with previous findings, Omicron variant exhibited the highest degree of immune evasion, rendering all different forms of inactivated vaccines substantially less efficacious. Notably, monovalent and bivalent Delta variant-specific inactivated vaccines provided optimal protection against challenge with Delta variant. Yet, some cross-variant protection against Omicron and Alpha variants was seen with all monovalent and bivalent inactivated vaccines tested. Taken together, our findings support the notion that an optimal next-generation inactivated vaccine against SARS-CoV-2 should contain the predominant VOC in circulation. Further investigations are underway to test whether a bivalent vaccine for Delta and Omicron variants can serve this purpose.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Biological Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectImmune protection-
dc.subjectInactivated vaccine-
dc.subjectNeutralizing antibodies-
dc.subjectSARS-CoV-2 variants of concern-
dc.titleCross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.7150/ijbs.72109-
dc.identifier.pmid35874942-
dc.identifier.pmcidPMC9305277-
dc.identifier.scopuseid_2-s2.0-85134159786-
dc.identifier.volume18-
dc.identifier.issue12-
dc.identifier.spage4781-
dc.identifier.epage4791-
dc.identifier.isiWOS:000828439300026-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats